3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Polycystic Ovary Syndrome
3
Peripheral Nervous System Diseases
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Carcinoma, Hepatocellular
3
Stomatitis
2
Stomach Neoplasms
2
Pseudomyxoma Peritonei
2
Ototoxicity
2
Neurofibromatosis 1
2
Neoplasms
2
Liver Neoplasms
2
Hearing Loss
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Weight Loss
1
Ulcer
1
Tongue Neoplasms
1
Tomaculous neuropathy
1
Thrombocythemia, Essential
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Renal Insufficiency, Chronic
1
Renal Artery Obstruction
1
Radiation-Induced Mucositis
1
Radiation Pneumonitis
1
Pulmonary Embolism
1
Primary Myelofibrosis
1
Primary Graft Dysfunction
1
Interventions
Pemetrexed
39
Cisplatin
33
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Imatinib Mesylate
3
Cerebral Decortication
3
tislelizumab
2
sargramostim
2
fludarabine phosphate
2
defactinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mesothelioma
×
Acetylcysteine
×
Clear all
NCT00637624
2022-08-25
NAC-PNP
Rijnstate Hospital
Phase NA
Terminated
69 enrolled